Forest's Lexapro approved in US for depression in adolescents
25 March 2009
Katie McQue
Please Login to read the full article.
25 March 2009
Katie McQue
katie.mcque@informa.com
The US FDA has approved Forest Laboratories' SSRI antidepressant Lexapro (escitalopram) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents aged 12 to 17 years old.
The only other product approved for this indication is Lilly's Prozac (fluoxetine) and...
Please Login to read the full article.
RELATED CONTENT
NEWS
- AstraZeneca to take $381.5 million charge after two major trial failures
- Otsuka and Lundbeck enter "historic" CNS alliance as patent expiries loom
- Europeans consider citalopram dosing after FDA action and Canadian review
- Major disappointment for Targacept and AstraZeneca in Phase III depression trial
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
